Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

Shares in Evotec jumped as much as 13.3% on Monday after regulatory filings showed private equity firm Triton had built an over 9% stake in the German drug development company.

Evotec shares soared after the company said private equity group Triton had acquired about 10% of its stock. Luxembourg-based private equity firm Triton acquired a total of 17,730,913 ordinary shares ...

Triton Partners, is considering a takeover bid Evotec , Eyk Henning of Bloomberg reported earlier, citing people familiar with the matter. Triton is among several investment firms ...

(Bloomberg) -- Triton Partners is considering a takeover bid for Germany’s Evotec SE, according to people familiar with the matter, after the private equity firm emerged as one of the drug developer’s ...

Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall around ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...

Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of ...

ADRs quickly rose 14% on a report that Halozyme Therapeutics (HALO) has expressed takeover interest. Halozyme has recently ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, ...